Table 2. Response to eculizumab therapy... | American Society of Hematology

Table 2.

Response to eculizumab therapy

Variable	OR	P
Log (sC5b-9) at TA-TMA diagnosis	0.28	.026
Log (sC5b-9 max) before starting eculizumab	0.15	.0014
rUPCR at TA-TMA diagnosis	0.76	.65
aGVHD diagnosed before TA-TMA*	0.96	.95
aGVHD diagnosed after TA-TMA*,†	0.3	.16

Variable	OR	P
Log (sC5b-9) at TA-TMA diagnosis	0.28	.026
Log (sC5b-9 max) before starting eculizumab	0.15	.0014
rUPCR at TA-TMA diagnosis	0.76	.65
aGVHD diagnosed before TA-TMA*	0.96	.95
aGVHD diagnosed after TA-TMA*,†	0.3	.16

The OR is from a univariate logistic regression model with response defined as a CR or a PR. An OR > 1 indicates that the variable corresponds to a decrease in the odds of a response.

aGVHD, acute GVHD.

Analysis excludes autologous HSCT recipients.

†

Analysis excludes those with aGVHD before TA-TMA.

View Large

This Feature Is Available To Subscribers Only